Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/02/2009US7541382 Prostaglandin analog compositions and methods to treat epithelial-related conditions
06/02/2009US7541381 Sulfur compounds such as 3-((4-chloroanilino)sulfonyl)thio-phene-2-carboxylic acid, used as enzymes inhibitors for prophylaxis of antibiotic resistant bacterial infections
06/02/2009US7541380 adminsterin rapmycin and a transcription process modifer such as cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphateb gaunosine diphosphateb and guanosine monophosphate to a human patient suffering from beta-thalassemia
06/02/2009US7541379 3,4-di(toluene-p-sulfonamido)-N-methyl-pyrrole; modulate osteoblastogenic differentiation; treating osteoporosis
06/02/2009US7541378 tert-butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate; N-benzyl-3-[(4-fluorobenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxamide; treats a disease caused associated with an altered (disregulated) protein kinase activity e.g cancer, cell proliferative disorders, Alzheimer's disease, viral infections
06/02/2009US7541377 1-[2-(Aminomethyl)phenyl]-N-[2-methyl-6-[[(1-methylethyl)amino]carbonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; pesticides
06/02/2009US7541376 3-(3-Fluoro-phenyl)-6-methoxy-1H-indazole-5-carboxylic acid(furan-2-ylmethyl)-amide; 3-Benzo[b]thiophen-2-yl-4-methoxy-1H-indazole-5-carboxylic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; Jun amino-terminal kinase (JNK) inhibitor; immunologic disease, inflammatory and neurodegenerative diseases
06/02/2009US7541375 Azole derivatives and pharmaceutical compositions containing them
06/02/2009US7541373 2-[3-(2-cyclopentanecarbonyl-4-methyl-phenyl)-ureido]-thiazol-4-yl} acetic acid; 2-[3-(4-Methyl-2-[2-methylpropoxy] phenyl)-ureido]-thiazol-4-yl}-acetic acid; activators of glucokinase; treatment of metabolic disorders, hyperglycemic agent, syndrome x, anticholesterol, hypertension etc.
06/02/2009US7541372 Cyclopropylmethyl-{3-methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-amine; -{3-Methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-thiomorpholine; useful for the treatment of cognitive disorders like Alzheimer's disease
06/02/2009US7541371 e.g. N-methyl-{1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl}acetamide having serotonin receptor antagonist activity; olanzapine, risperidone, perospirone, quetiapine, clocapramine, carpipramine, mosapramine, chlorpromazine,levomeromazine, trazodone, imipramine, paroxetine, fluoxamine etc
06/02/2009US7541370 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
06/02/2009US7541369 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2009US7541368 Pyrazoles as inhibitors of tumor necrosis factor
06/02/2009US7541367 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
06/02/2009US7541366 Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof
06/02/2009US7541365 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation
06/02/2009US7541364 Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence of mu agonists.
06/02/2009US7541363 (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; excellent solubility, stability, bioavailability, dispersing property; adenosine A2 receptor antagonistic activity; treats Parkinson disease, senile dementia, depression, asthma and osteoporosis
06/02/2009US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine
06/02/2009US7541361 N-[4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use
06/02/2009US7541360 2-amino-4-N-cyclohexylmethylamino-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-pteridine; treatment of pathological blood pressure decreases, such as occur in septic or hemorrhagic shock, in tumor or cancer therapy with cytokines, liver cirrhosis; ulcerative colitis; NO synthase inhibitor
06/02/2009US7541359 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
06/02/2009US7541358 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
06/02/2009US7541357 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
06/02/2009US7541356 Compounds for use in weight loss and appetite suppression in humans
06/02/2009US7541355 Conversion process for 2,3-benzodiazepine enantiomers
06/02/2009US7541354 Bicyclo-pyrazoles
06/02/2009US7541353 Enzyme inhibitors; interferons; interleukins; cyclosporins
06/02/2009US7541352 Compounds for the treatment of hepatitis C
06/02/2009US7541351 Compounds for the treatment of hepatitis C
06/02/2009US7541350 Formulation containing anti-inflammatory androstane derivative
06/02/2009US7541349 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone
06/02/2009US7541347 Controlled release carrier selected from hydroxypropyl methyl cellulose, hydroxypropyl cellulose, and polyvinylpyrrolidone; improved pharmacokinetics as compared to immediate-release minocycline hydrochloride; side effect reduction
06/02/2009US7541346 Pancratistatin cyclic phosphate prodrugs and phenpanstatin cyclic phosphate prodrugs
06/02/2009US7541344 Modulation of survivin expression
06/02/2009US7541343 Antiproliferative agents; administering protein; restenosis, atherosclerosis; cancer
06/02/2009US7541342 Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents
06/02/2009US7541341 2-(4-ethylbenzyl)-5-hydroxymethylphenyl 6-O-ethoxycarbonyl- beta -D-glucopyranoside; for treatment/prevention of hyperglycemia associated with diabetes/obesity
06/02/2009US7541337 Methods and compositions for the treatment of peripheral artery disease
06/02/2009US7541332 reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity
06/02/2009US7541329 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
06/02/2009US7541179 Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies
06/02/2009US7541047 Method for production of shaped body for treating wounds in milk producing animals
06/02/2009US7541045 Concentrated, non-foaming solution of quaternary ammonium compounds and methods of use
06/02/2009US7541044 stimulating antitumor immune responses; tissue-targeted therapy; first tumour antigen is used to treat secondary tumor; biodrug for cancer immunotherapy with cyclophosphamide
06/02/2009US7541042 Topical compositions containing Bacillus coagulans extracellular products and uses thereof
06/02/2009US7541032 Antigen uptake receptor for Candida albicans on dendritic cells
06/02/2009US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα
06/02/2009US7541024 A stable polyallylamine hydrochloride polymer crosslinked by epichlorohydrin
06/02/2009US7541022 Pharmaceutical formulations for dry powder inhalers
06/02/2009CA2534024C Novel compounds having inhibitory activity against sodium-dependant transporter
06/02/2009CA2526954C Antibiotics containing bone substitute material with sustained active substance release
06/02/2009CA2516433C Ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
06/02/2009CA2512475C Compositions and methods for combination antiviral therapy
06/02/2009CA2503900C Purine compounds and use thereof as cannabinoid receptor ligands
06/02/2009CA2474003C Process for the preparation of high purity perindopril and intermediates useful in the synthesis
06/02/2009CA2452253C Novel crystal of arylethenesulfonamide derivative and preparation process thereof
06/02/2009CA2450868C Non-nucleoside reverse transcriptase inhibitors
06/02/2009CA2450787C Active ingredient combination for pharmacological addictive substance or intoxicant therapy
06/02/2009CA2434277C Substituted alkylamine derivatives and methods of use
06/02/2009CA2433833C Use of flumazenil in developing a drug for the treatment of alcohol dependence
06/02/2009CA2427814C A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
06/02/2009CA2425395C Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
06/02/2009CA2410160C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
06/02/2009CA2396223C Instant granules and process for their formulation
06/02/2009CA2394606C New modulators of dopamine neurotransmission
06/02/2009CA2392025C Process for the preparation of amorphous atorvastatin
06/02/2009CA2387143C Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
06/02/2009CA2386890C Artificial tear replacement solution
06/02/2009CA2381187C Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis
06/02/2009CA2380455C 9a-azalides with antibacterial activity
06/02/2009CA2377230C Benzimidazole compounds and medicaments comprising the same
06/02/2009CA2371728C High dose radionuclide complexes for bone marrow suppression
06/02/2009CA2366793C Propofol formulation with enhanced microbial characteristics
06/02/2009CA2362594C Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
06/02/2009CA2362558C Antithrombotic use of glycine betaine
06/02/2009CA2350425C Use of an insulin sensitiser for the treatment of type 2 diabetes mellitus
06/02/2009CA2349719C Controlled delivery of antidepressants
06/02/2009CA2349633C A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
06/02/2009CA2344290C Quinazoline derivatives
06/02/2009CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent
06/02/2009CA2334308C Hyperforin derivatives, the use thereof and formulations containing them
06/02/2009CA2330647C Carnitine supplemented diet to prevent or alleviate ascites in broiler type poultry
06/02/2009CA2326137C Method for stabilizing pharmaceutical compositions by special use of an antioxidant
06/02/2009CA2321664C Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
06/02/2009CA2309104C Metal/thiol biocides
06/02/2009CA2304950C Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
06/02/2009CA2287551C 3-(2-pyrrolidinylmethyl)-indole compounds having 5-ht6 affinity
06/02/2009CA2277865C Method of inhibiting cancer growth
06/02/2009CA2258539C Ring-fused dihydropyranes, process for the preparation and use thereof
06/02/2009CA2257329C Nebulized budesonide for the treatment of respiratory diseases
06/02/2009CA2244089C Dermal penetration enhancers and drug delivery systems involving same
06/02/2009CA2229010C Mannose-6-phosphate analogues for the treatment of wounds and fibrotic disorders with reduced scarring
06/02/2009CA2211802C Pharmaceutical composition for the treatment of herpes
06/02/2009CA2190867C Methods for reduced renal uptake of antibody fragments
05/2009
05/30/2009CA2612999A1 Modified release composition of at least one form of venlafaxine
05/29/2009CA2645441A1 Compositions of tolperisone
05/28/2009WO2009067703A2 Tapentadol compositions
05/28/2009WO2009067699A2 Methods for providing a system of care for an oxazaphosphorine drug regimen